Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.

ABSTRACT:

Objectives

To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.

Design

Blinded, prospective multicenter observational clinical trial following an Food and Drug Administration-approved protocol.

Setting

Thirteen U.S.-based emergency departments and ICUs.

Patients

Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emergency department, other wards, or directly from out of hospital were included.

Interventions

Procalcitonin was measured daily over the first 5 days.

Measurements and main results

The

SUBMITTER: Schuetz P 

PROVIDER: S-EPMC5389588 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature